HemoSonics, a medical device technology company based in the United States, has won an award in the Innovation category in the 2024 Medical Device Network Excellence Awards for its Quantra Hemostasis System. This diagnostic device is the only one of its kind cleared by the U.S. Food and Drug Administration for use across four major indications, including cardiac, trauma, liver transplantation, and major orthopaedic surgeries.
Recommended Buyer's Guides
The Medical Device Network Excellence Awards celebrate the greatest achievements and innovations in the industry. Powered by the business intelligence of GlobalData, the programme provides a platform to recognise the people and companies that are driving change.
Go deeper with GlobalData
The award recognises HemoSonics’ innovative approach to hemostasis analysis, offering rapid, comprehensive blood testing and improving patient care in surgical and critical care settings.
Revolutionising surgical blood analysis with Quantra
Before the advent of Quantra, existing whole blood viscoelastic testing technologies were too slow and cumbersome for practical use in real-time guidance of blood product transfusions. Quantra’s design addresses these challenges, offering an easy-to-operate, interpret, and maintain system that can be fully operationalised in acute care hospitals.
The patented SEER Sonorheometry technology is the heart of the system and utilises novel ultrasound pulses which measure the viscoelasticity of whole blood samples as clots form, offering a new means for measuring coagulation.
Quantra’s ability to provide detailed blood analysis within 15 minutes directly in the operating room and critical care areas is a game-changer. This rapid turnaround time is crucial during complex surgeries, or during recovery, allowing for rapid and appropriate interventions. The system’s efficiency can contribute to significant blood resource savings for hospitals, and helps clinicians optimise transfusions, which is better for patients.
Advancing global healthcare standards and efficiency
The World Health Organization’s 2021 call for the implementation of patient blood management as a standard of care underscores the relevance of the Quantra System. By improving testing and preserving blood supplies, Quantra aligns perfectly with these global healthcare standards, demonstrating its role in enhancing patient outcomes while also reducing healthcare costs.
The system helps conserve community blood supplies and related costs. It can also help reduce unnecessary surgical repoerations which in-turn increase ICU recovery times. Its comprehensive internal quality control (QC) and intuitive design make it an ideal point of care solution in busy perioperative settings.
Enhancing usability and integration with Quantra’s design
As the next-generation of viscoelastic hemostasis testing, Quantra boasts a fully-automated, sealed cartridge-based system that is flexible and robust. Its quick learning curve, simple workflow, and strong correlation with standard laboratory tests make it an indispensable tool for healthcare providers.
The system’s integration into existing IT infrastructures and remote access capabilities further enhance its appeal.
Additionally, the Quantra System’s ease of use is exemplified by its three-push workflow and the fact that it requires less than one minute of hands-on time to initiate a test. After a short, 30-minute training, new users were able to read and interpret the results with 95% proficiency, showcasing the system’s user-friendly nature.
Innovative technology ensuring quality control
The Quantra System also eliminates the need for pipetting, is robust to vibration, and provides excellent precision, making it suitable for use in point-of-care (POC) or clinical laboratory settings. The system’s internal QC runs automatically every eight hours and with every test, ensuring reliability without the need for additional QC prior to use.
The Quantra System’s actionable outputs and easy-to-read results screens are designed to be intuitive, with dials, trends, and curves displays that aid in the interpretation of comprehensive results at a glance. This level of innovation and user-centric design is what sets the Quantra System apart in the field of viscoelastic hemostasis testing.
“The Quantra Hemostasis System provides comprehensive whole-blood coagulation analysis at the point of care in less than 15 minutes and now has the broadest range of FDA-cleared clinical indications of any cartridge-based viscoelastic testing system, including cardiac, trauma, liver, and major orthopaedic surgeries. Blood is a precious resource, and providing the best patient care is paramount. We’re proud that our technology enables clinicians to make better and more informed blood transfusion decisions, improves care for the patients that we serve, and helps preserve blood for patients in critical need.”
– Bob Roda, President and Chief Executive Officer
Company Profile
HemoSonics, LLC is a medical device technology company focused on acute bleeding management, resulting in better patient care and lower overall medical costs. The Quantra Hemostasis Analyzer, HemoSonics’ flagship product, is designed to improve patient outcomes and reduce healthcare costs by providing optimised coagulation information.
The Quantra System’s easy and fast interpretation enables simple, more efficient point-of-care and laboratory bleeding management. Based in Durham, NC, HemoSonics is part of the Stago Group, a leading in vitro diagnostics company dedicated to exploring thrombosis and hemostasis.
Contact Details
John Friedl,
Director, Global Marketing,
HemoSonics
Website: https://hemosonics.com/
Links
